Products
Companies
News
About
About
FAQ
Contact
Contact
Newsletter
×
Subscribe to our monthly newsletter
Subscribe
Products
RevealAI-Lung
RevealAI-Lung
RevealDx
RevealAI™ is Computer Assisted Diagnostic (CADx) software that reveals patterns within images and across patients. The analytics generate scores for the current patient by comparing abnormalities to other patients that have confirmed diagnostics. RevealAI-Lung provides a Malignancy Similarity Index (mSI) from lung CT scans that aids risk assessment. Graphs are provided that help interpret how lung nodules from the current patient relate to confirmed malignant or benign nodules.
Information source:
Vendor
Last updated:
November 7, 2024
General Information
Technical Specifications
Regulatory
Market
Evidence
General Information
General
Product name
RevealAI-Lung
Company
RevealDx
Subspeciality
Chest
Modality
CT
Disease targeted
Lung cancer
Key-features
Nodule malignancy similarity score
Suggested use
During: interactive decision support (shows abnormalities/results only on demand)
Technical Specifications
Data characteristics
Population
Incidental nodules and those found during screening
Input
CT, 3D, contrast, non-contrast
Input format
DICOM
Output
Malignancy Similarity Index (mSI)
Output format
To be determined
Technology
Integration
Integration in standard reading environment (PACS)
Deployment
Locally on dedicated hardware, Cloud-based
Trigger for analysis
On demand, triggered by a user through e.g. a button click, image upload, etc.
Processing time
< 3 sec
Regulatory
Certification
CE
Certified, Class IIa
, MDD
FDA
No or not yet
Intended Use Statements
Intended use (according to CE)
Design and manufacture of software intended as a decision aid for analysis of computed tomography (CT) scans of the lung for cancer diagnosis.
Market
Market presence
On market since
05-2021
Distribution channels
contextflow, Amplify SDK, Riverain Technologies
Countries present (clinical, non-research use)
Paying clinical customers (institutes)
Research/test users (institutes)
2
Pricing
Pricing model
Pay-per-use, Subscription
Based on
Number of analyses
Evidence
Evidence
Peer reviewed papers on performance
Clinical Impact and Generalizability of a Computer-Assisted Diagnostic Tool to Risk-Stratify Lung Nodules With CT
(read)
Non-peer reviewed papers on performance
Other relevant papers